Helen Dakin
Publications and Insights
- Publication: The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases
- Bulletin: Two perspectives on perspective
- Insight: Why do we expect obesity medicines to work differently?
- Publication: The case for adopting a broader perspective on value in Health Technology Assessment
- Publication: Patient preferences for treatment in relapsed/refractory acute leukemia
- Publication: Understanding the preferences of people with acute leukemia for different health outcomes
- Bulletin: From £44bn losses to HTA reform
- Bulletin: Health economics and HTA: milestones and new directions
- Insight: Prevention pays off – so why aren’t we doing more of it?
- Publication: Analysing Global Immunisation Expenditure
- Insight: Around the World in HTAs: Canada – Autonomous yet Collaborative
- Bulletin: Turning differences into progress
- Publication: Understanding societal preferences for priority by disease severity in England & Wales
- Bulletin: Who gets what? Health economics in action
- Insight: Around The World in HTAs: Thailand – An Ever-Evolving Policy Tool
- Publication: Socio-Economic Value of Adult Immunisation Programmes
- Publication: Incorporating the Patient Voice in Health Technology Assessment
- Publication: Developing a Conceptual Framework of Healthcare System Pressure
- Insight: Looking Further Afield – What Can Health Economics Learn from the Environmental Economics Approach to Discounting?
- Publication: Individual, Health System, and Societal Impacts of Anti-seizure Medicine Use During Pregnancy
- Publication: Capturing the Broader Value of Antibiotics
- Publication: NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?
- Publication: The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society
- Insight: Caring about Carers: Improving Consideration of the Burden of Informal Caring in HTA
- Publication: Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism
- Insight: Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
- Publication: Navigating the Landscape of Digital Health – United Kingdom
- Publication: After the Transplant: Potential Benefits for the NHS and UK Kidney Transplant Patients
- Publication: The Value of Vaccines in Maintaining Health System Capacity in England
- Publication: A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
- Publication: Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?
- New: Opportunities to Increase Efficiency in Healthcare
- Publication: Opportunities to Increase Efficiency in Healthcare
- Publication: The Broader Value of Vaccines: The Return on Investment From a Governmental Perspective
- Publication: Realising the Broader Value of Vaccines in the UK
- Publication: Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies
- Publication: Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions
- Publication: The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment